Introduction
Ultromics is an Oxford-based health technology company founded in 2017 that applies artificial intelligence to echocardiography — the most widely used modality for diagnosing cardiovascular disease. Ross Upton, PhD, founded Ultromics from University of Oxford research alongside Professor Paul Leeson and serves as chief executive officer per the company’s about page and July 31, 2025 Series C announcement reviewed in July 2026.
Ultromics’ EchoGo platform is FDA-cleared and Medicare-reimbursed, analyzing standard ultrasound scans without new hardware — a deployment model health systems favor when echo lab capacity is constrained and subjective interpretation contributes to missed HFpEF and cardiac amyloidosis diagnoses.
What the company does
Ultromics builds AI that reads echocardiograms to detect complex heart conditions earlier than conventional visual assessment. EchoGo Core provides automated strain and ejection fraction analysis cleared by FDA in November 2019. Subsequent products target heart failure with preserved ejection fraction and cardiac amyloidosis — conditions Ultromics cites as frequently missed because echo findings are subtle and interpreter experience varies widely across community hospitals.
The July 2025 Series C release states Ultromics has analyzed more than 430,000 echocardiograms, with clinical studies showing EchoGo improved HFpEF detection by 73.6% compared with standard clinical risk scores — quantified outcomes hospital value committees can benchmark against manual reads alone.
Who it serves
Ultromics serves cardiology departments and echo labs at U.S. health systems including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic partners cited in its Series C release, alongside NHS England collaborations from the company’s Oxford origins. Medicare reimbursement for outpatient and inpatient EchoGo use gives finance teams a reimbursement anchor uncommon among early-stage imaging AI vendors still pursuing coverage.
Echo sonographers and cardiologists evaluate Ultromics on workflow integration — whether AI probability scores appear inside existing reporting systems without adding scan time or requiring dedicated AI workstations.
Company background
Upton developed Ultromics’ underlying algorithm as a sonographer and doctoral researcher at Oxford, designing AI that bypasses subjective echo interpretation limitations Leeson’s lab had documented for years. Ultromics spun out in 2017, earned early NHS England support, Forbes 30 Under 30 recognition for Upton in 2019, and successive FDA clearances culminating in Breakthrough Device designation for EchoGo Amyloidosis in late 2024.
The July 2025 $55 million Series C co-led by L&G, Allegis Capital, and Lightrock — with participation from Oxford Science Enterprises, GV, UCM Ventures, and UPMC Enterprises — funds U.S. scaling at a moment Ultromics describes as a heart failure crisis driving health-system demand for AI-enhanced echo diagnostics.
Product and AI capabilities
EchoGo applies deep learning to standard echocardiogram DICOM studies, generating real-time probability scores for HFpEF and cardiac amyloidosis rather than automating measurements alone. Ultromics trained models on one of the largest real-world echo datasets cited in its press materials, validated across 25 peer-reviewed studies including European Heart Journal publication for amyloidosis detection across 18 global institutions.
2025 product additions include EchoGo Score probability scoring on EchoGo Heart Failure and CMS outpatient APC reimbursement updates — linking clinical capability to payment mechanics hospitals require before enterprise rollout.
Key developments
2017: Ultromics founded in Oxford by Ross Upton. November 14, 2019: FDA clearance for EchoGo Core. Late 2024: FDA Breakthrough Device clearance for EchoGo Amyloidosis. July 31, 2025: $55M Series C announced (ultromics.com, official source). 2025–2026: EchoGo Score launch; Medicare reimbursement for heart failure and amyloidosis products.
Why it matters
Ultromics matters because heart failure drives over $30 billion in annual U.S. healthcare costs projected to exceed $70 billion by 2030 — yet millions remain undiagnosed until decompensation. AI that runs on existing echo infrastructure lets hospitals attack underdiagnosis without capital equipment budgets. Ultromics complements Caristo Diagnostics cardiac CT inflammation scoring while sharing Oxford academic DNA with Optellum thoracic AI.
Sector context
Ultromics belongs in Brel’s AI in healthcare coverage under medical imaging and cardiovascular AI alongside Caristo Diagnostics. Echo-based AI addresses different clinical entry points than CCTA inflammation analysis — buyers may deploy both across preventive cardiology programs serving distinct patient pathways.
Sources and references
Ultromics Series C press release (July 31, 2025) and About Ultromics page.
- Ultromics — $55M Series C (ultromics.com, July 31, 2025)
- Ultromics — About Ultromics (ultromics.com)
Reviewed July 10, 2026. Ross Upton, PhD, is founder and CEO.